Related Experiment Video

Updated: Aug 16, 2026

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians
06:49

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians

Published on: March 14, 2014

Protective effect of a PAF-acether antagonist, BN 52021, in trichothecene toxicosis

G Feuerstein1, P Leader, A L Siren

  • 1Department of Neurology, Uniformed Services University of the Health Sciences, Bethesda, MD 20814-4799.

Toxicology Letters
|October 1, 1987
PubMed

Insights

The study shows that BN 52021, a platelet activating factor (PAF) antagonist, can extend survival in rats exposed to lethal T-2 toxin. This suggests PAF plays a key role in T-2 toxicosis.

Area of Science:

  • Toxicology
  • Pharmacology
  • Mycotoxicology

Background:

  • Trichothecenes are potent mycotoxins causing severe toxicosis in humans and animals.
  • Current therapeutic options for trichothecene poisoning are inadequate.
  • Platelet activating factor (PAF) is implicated in various toxicological responses.

Purpose of the Study:

  • To investigate the therapeutic potential of a selective PAF antagonist against T-2 toxicosis.
  • To determine the role of PAF as a mediator in T-2 mycotoxicosis.

Main Methods:

  • Administration of the PAF antagonist BN 52021 (5-15 mg/kg i.v.) to conscious rats.
  • Exposure of rats to a highly lethal dose of T-2 toxin.
  • Monitoring of survival rates and assessment of toxicosis severity.

Main Results:

  • BN 52021 significantly prolonged the survival time of rats exposed to T-2 toxin.
  • The protective effect was observed at doses of 5-15 mg/kg i.v.
  • These findings indicate a crucial role for PAF in the pathogenesis of T-2 toxicosis.

Conclusions:

  • Selective PAF antagonism demonstrates therapeutic potential against T-2 mycotoxicosis.
  • PAF is identified as a significant mediator in T-2 toxin-induced lethal toxicosis.
  • Further research into PAF-targeted therapies for mycotoxin poisoning is warranted.

More Related Videos

Caenorhabditis elegans as a Model System for Discovering Bioactive Compounds Against Polyglutamine-Mediated Neurotoxicity08:16

Caenorhabditis elegans as a Model System for Discovering Bioactive Compounds Against Polyglutamine-Mediated Neurotoxicity

Published on: September 21, 2021

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B11:44

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B

Published on: January 19, 2022

Related Concept Videos

Desensitization and Tachyphylaxis01:20

Desensitization and Tachyphylaxis

Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
Several...
Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...